Payment overview · 2025
General Payments
$455.81
22 reported records · 14 companies
Healthcare provider profile · identity verified
Jagdeep Singh Bal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROSEVILLE, CA · NPI 1548252703
Verified facts
What the public records show
CMS Open Payments records show Jagdeep Singh Bal, M.D. received $455.81 in general payments during 2025 across 22 reported records.
Janssen Biotech, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $75.55 | 16.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.84 | 12.2% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $42.95 | 9.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.37 | 9.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.04 | 8.3% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $35.25 | 7.7% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $27.79 | 6.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.79 | 5.2% | 1 | 2025 |
| Biocon Biologics Inc | Unresolved — no canonical attribution shown | $22.90 | 5.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.25 | 4.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.67 | 4.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $19.14 | 4.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.24 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.03 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.81 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $75.55 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.84 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| Hulio Normalized: hulio |
Drug | Biocon Biologics Inc | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 136 |
| Metformin Hcl | Metformin Hcl | 284 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 59 |
| Omeprazole | Omeprazole | 204 | 52 |
| Lisinopril | Lisinopril | 197 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 41 |
| Losartan Potassium | Losartan Potassium | 161 | 48 |
| Montelukast Sodium | Montelukast Sodium | 146 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 38 |
| Gabapentin | Gabapentin | 130 | 28 |
| Jardiance | Empagliflozin | 123 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 29 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 91 | 11 |
| Trazodone Hcl | Trazodone Hcl | 83 | 21 |
| Furosemide | Furosemide | 75 | 23 |
| Januvia | Sitagliptin Phosphate | 70 | 16 |
| Allopurinol | Allopurinol | 68 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 17 |
| Ozempic | Semaglutide | 62 | suppressed |
| Potassium Chloride | Potassium Chloride | 61 | 15 |
| Sertraline Hcl | Sertraline Hcl | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 57 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 16 |
| Methotrexate | Methotrexate Sodium | 55 | 12 |
| Prednisone | Prednisone | 55 | 23 |
| Glimepiride | Glimepiride | 54 | 12 |
| Dutasteride | Dutasteride | 51 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Baclofen | Baclofen | 42 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 17 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Enbrel Sureclick | Etanercept | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.81 · 22 records | Janssen Biotech, Inc. | APRETUDE, APTIMA, AREXVY, Dexcom G6 Transmitter, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Grastek, Hulio, Kerendia, Odactra, Ozempic, PURIFIED CORTROPHIN GEL, Ragwitek, Rybelsus, SHINGRIX, SUBLOCADE, TREMFYA, VOQUEZNA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error